Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study

The ocular AEs occurred frequently in patients receiving bemarituzumab, requiring close ophthalmic monitoring and prophylactic administration of FGF-based eye drops. Collaboration between oncologists and ophthalmologists is critical for the timely management of treatment-related AEs, which could ultimately improve overall clinical outcomes.